Our findings demonstrate that SFV vectors, particularly those engineered to deliver TNFα or IFNγ, can reprogramme macrophages towards an anti-tumour phenotype, with substantial implications for cancer immunotherapy. This evidence concerns the gene IFNG and cancer.